Literature DB >> 10211100

High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer.

J C Saurin1, J P Rouault, J Abello, F Berger, L Remy, J A Chayvialle.   

Abstract

The neuropeptide bombesin stimulates tumour cell proliferation in vitro. Through pharmacological testing, 20-40% of human colorectal tumours have been shown to be equipped with bombesin/gastrin releasing peptide receptor (GRP-R). The aim of the present study was to test whether GRP-R expression is correlated with tumour characteristics and usual prognostic factors in colorectal adenocarcinomas. A sensitive reverse transcription (RT)-competitive polymerase chain reaction (PCR) method was validated by studying GRP-R mRNA in separated layers of normal colonic wall, and GRP-R mRNA levels (in parallel with binding studies) in colon cancer cell lines LoVo and Caco-2. GRP-R mRNA levels were then determined in 29 surgical tumour specimens and the results compared with tumour histology and, using histochemistry, with the accumulation of p53 protein and a Ki-67 cell proliferation index. The mRNA was not detected in normal colonic epithelium, whereas a distinct signal was observed after amplification in 27/29 (93%) tumour specimens. Estimates of mRNA levels in the 27 positive tumours ranged from 52 to 8000 amol/0.25 microgram total RNA, and were significantly higher in poorly/moderately differentiated tumours (P < 0.05) and in tumours with lymphatic vessel invasion (P < 0.01). There was no relationship with p53 accumulation or to the proliferation index. Our results show that GRP-R mRNA can be detected in most colorectal tumour specimens, and suggest a link between high mRNA levels and both tumour dedifferentiation and lymph vessel invasion, but not proliferation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211100     DOI: 10.1016/s0959-8049(98)00276-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA expression in non-tumor tissues of the human gastrointestinal tract.

Authors:  Hans-Jurg Monstein; Niclas Grahn; Mikael Truedsson; Bodil Ohlsson
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Differences in plasma gastrin, CEA, and CA 19-9 concentration in patients with proximal and distal colorectal cancer.

Authors:  Grzegorz Bombski; Anita Gasiorowska; Daria Orszulak-Michalak; Beata Neneman; Justyna Kotynia; Janusz Strzelczyk; Adam Janiak; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2002

3.  Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.

Authors:  Ferenc G Rick; Stefan Buchholz; Andrew V Schally; Luca Szalontay; Awtar Krishan; Christian Datz; Andreas Stadlmayr; Elmar Aigner; Roberto Perez; Stephan Seitz; Norman L Block; Florian Hohla
Journal:  Cell Cycle       Date:  2012-07-01       Impact factor: 4.534

Review 4.  Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Authors:  Florian Hohla; Thomas Winder; Richard Greil; Ferenc G Rick; Norman L Block; Andrew V Schally
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

5.  In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.

Authors:  Regi Thomas; Jianqing Chen; Martine M Roudier; Robert L Vessella; Laura E Lantry; Adrian D Nunn
Journal:  Clin Exp Metastasis       Date:  2008-10-31       Impact factor: 5.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.